Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bomedemstat + Maintenance Atezolizumab in ES-SCLC
NCT05191797Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bomedemstat in small cell lung cancer (SCLC), sponsored by University of Washington. Started Apr 2022; status: terminated.
02
Drugs
bomedemstat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05191797.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05191797.